Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT07564726

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
Celltrion Pharm, Inc. (from the registry)
Registry
  • NCT NCT07564726
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07564726. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-05 (actual); primary completion 2024-02-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
Condition
Hypertension
Condition
Hypercholesterolemia
Intervention (Drug)
Amlodipine
Intervention (Drug)
Ezetimibe/Rosuvastatin
Intervention (Drug)
Ezetimibe/Rosuvastatin Placebo
Intervention (Drug)
Amlodipine Placebo
Lead sponsor
Celltrion Pharm, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07564726
Content hash
faf9fa73d4241a938ae4b5e705f56680cb6dc6c16e2b90da8c502cf56fecfe0f